Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biochim Biophys Acta Mol Basis Dis ; 1864(1): 296-306, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29107807

RESUMO

The RNA-binding protein, HuR, modulates mRNA processing and gene expression of several stress response proteins i.e. Hsp70 and p53 that have been postulated to be involved in the pathogenesis of glaucoma, a chronic optic neuropathy leading to irreversible blindness. We evaluated HuR protein expression in retinas and optic nerves of glaucomatous rats and human primary open angle glaucoma patients and its possible impact on stress response mechanisms. We found that the cytoplasmic content of HuR was reduced more extensively in glaucomatous retinas than in optic nerves and this was linked with a declined cytoplasmic Hsp70 level and p53 nuclear translocation. In the optic nerve, the p53 content was decreased as a feature of reactive gliosis. Based on our findings, we conclude that the alteration in the HuR content, observed both in rat glaucoma model and human glaucoma samples, affects post-transcriptionally the expression of genes crucial for maintaining cell homeostasis; therefore, we postulate that HuR may be involved in the pathogenesis of glaucoma.


Assuntos
Proteína Semelhante a ELAV 1/metabolismo , Hipertensão Ocular/metabolismo , Células Ganglionares da Retina/metabolismo , Animais , Estudos de Casos e Controles , Modelos Animais de Doenças , Proteína Semelhante a ELAV 1/genética , Glaucoma de Ângulo Aberto/genética , Glaucoma de Ângulo Aberto/metabolismo , Glaucoma de Ângulo Aberto/patologia , Humanos , Pressão Intraocular/genética , Masculino , Neuroproteção/genética , Hipertensão Ocular/genética , Hipertensão Ocular/patologia , Nervo Óptico/metabolismo , Nervo Óptico/patologia , Ratos , Ratos Wistar , Células Ganglionares da Retina/patologia , Distribuição Tecidual
2.
Data Brief ; 24: 103865, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31016214

RESUMO

A growth cone is a part of a neuron considered as a hub for axon growth, motility and guidance functions. Growth cones are thought to play a critical role during development of neurons. Growth cones also play a significant role in adult regeneration. Here, we present a dataset on the lipid and protein profiling of the growth cone-enriched fractions derived from C57BL/6J mice forebrains of developmental stage: E18, P0, P3, P6, and P9. For comparison, we analyzed non-growth cone membranes from the same samples. Lipid data is available at the Metabolomics Workbench [http://www.metabolomicsworkbench.org (Project ID: PR000746)]. Protein data is available at Proteomics Identifications (PRIDE) partner repository (PRIDE identifier PXD012134).

3.
Data Brief ; 25: 103966, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31508459

RESUMO

We present lipid profiling data from mouse retina and optic nerve after optic nerve crush and during Wnt3a-induced axonal regeneration at 7 and 15 days post-crush. This data is available at the Metabolomics Workbench, http://www.metabolomicsworkbench.org (Project ID: PR000718).

4.
Data Brief ; 24: 103950, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31193141

RESUMO

In adult mammals, retinal ganglion cells (RGCs) fail to regenerate following damage. As a result, RGCs die after acute injury and in progressive degenerative diseases such as glaucoma; this can lead to permanent vision loss and, eventually, blindness. Lipids are crucial for the development and maintenance of cell membranes, myelin sheaths, and cellular signaling pathways, however, little is known about their role in axon injury and repair. Studies examining changes to the lipidome during optic nerve (ON) regeneration could greatly inform treatment strategies, yet these are largely lacking. Experimental animal models of ON regeneration have facilitated the exploration of the molecular determinants that affect RGC axon regeneration. Here, we analyzed lipid profiles of the ON and retina in an ON crush rat model using liquid chromatography-mass spectrometry. Furthermore, we investigated lipidome changes after ON crush followed by intravitreal treatment with Zymosan, a yeast cell wall derivative known to enhance RGC regeneration. This data is available at the NIH Common Fund's Metabolomics Data Repository and Coordinating Center (supported by NIH grant, U01-DK097430) website, the Metabolomics Workbench, http://www.metabolomicsworkbench.org, where it has been assigned Project ID: PR000661. The data can be accessed directly via it's Project DOI: doi: 10.21,228/M87D53.

5.
Redox Biol ; 21: 101062, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30576925

RESUMO

L-ascorbate (L-ASC) is a widely-known dietary nutrient which holds promising potential in cancer therapy when given parenterally at high doses. The anticancer effects of L-ASC involve its autoxidation and generation of H2O2, which is selectively toxic to malignant cells. Here we present that thioredoxin antioxidant system plays a key role in the scavenging of extracellularly-generated H2O2 in malignant B-cells. We show that inhibition of peroxiredoxin 1, the enzyme that removes H2O2 in a thioredoxin system-dependent manner, increases the sensitivity of malignant B-cells to L-ASC. Moreover, we demonstrate that auranofin (AUR), the inhibitor of the thioredoxin system that is used as an antirheumatic drug, diminishes the H2O2-scavenging capacity of malignant B-cells and potentiates pharmacological ascorbate anticancer activity in vitro and in vivo. The addition of AUR to L-ASC-treated cells triggers the accumulation of H2O2 in the cells, which results in iron-dependent cytotoxicity. Importantly, the synergistic effects are observed at as low as 200 µM L-ASC concentrations. In conclusion, we observed strong, synergistic, cancer-selective interaction between L-ASC and auranofin. Since both of these agents are available in clinical practice, our findings support further investigations of the efficacy of pharmacological ascorbate in combination with auranofin in preclinical and clinical settings.


Assuntos
Ácido Ascórbico/farmacologia , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Peróxido de Hidrogênio/metabolismo , Leucemia de Células B/metabolismo , Linfoma de Células B/metabolismo , Tiorredoxinas/metabolismo , Animais , Linfócitos B/efeitos dos fármacos , Linfócitos B/metabolismo , Linfócitos B/patologia , Linhagem Celular , Linhagem Celular Tumoral , Modelos Animais de Doenças , Humanos , Ferro/metabolismo , Leucemia de Células B/tratamento farmacológico , Leucemia de Células B/patologia , Linfoma de Células B/tratamento farmacológico , Linfoma de Células B/patologia , Camundongos , Ensaios Antitumorais Modelo de Xenoenxerto
6.
Methods Mol Biol ; 1695: 89-95, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29190021

RESUMO

iTRAQ 4plex method enables multiplexing of up to four samples for simultaneous quantitation to improve sensitivity and scope of proteomic analysis. Here, we describe iTRAQ 4plex labeling of human aqueous humor specimens followed by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) and data analysis for peptide identification and quantitation using Proteome Discoverer software. The protocol can be applied for other animals as well; however, pooling of specimens may be required to obtain sufficient amount of protein for labeling.


Assuntos
Humor Aquoso/metabolismo , Proteômica/métodos , Cromatografia Líquida de Alta Pressão , Humanos , Software , Coloração e Rotulagem , Espectrometria de Massas em Tandem
7.
Methods Mol Biol ; 1695: 97-107, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29190022

RESUMO

This protocol provides a step-by-step guide to shotgun sphingolipid analysis of aqueous humor. We describe the Bligh and Dyer crude lipid extraction method and electrospray ionization tandem mass spectrometry (ESI-MS/MS) coupled with MZmine 2.21 data processing for identification and ratiometric quantitation of sphingosine, sphingosine-1-phosphate, sphingomyelin, and ceramide.


Assuntos
Humor Aquoso/química , Esfingolipídeos/análise , Ceramidas/análise , Humanos , Lisofosfolipídeos/análise , Software , Espectrometria de Massas por Ionização por Electrospray/métodos , Esfingomielinas/análise , Esfingosina/análogos & derivados , Esfingosina/análise , Espectrometria de Massas em Tandem/métodos
8.
Eur J Pharmacol ; 788: 12-20, 2016 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-27288881

RESUMO

Success of the long-term glaucoma therapy and preservation of the visual function strongly depend on patients' compliance which may be affected by the inconvenience of treatment and its side effects. Recently, introduction of preservative-free anti-glaucoma agents has become an important step towards improved glaucoma care by eliminating the negative effects of preservatives on the eye surface. Although, newly developed eye drop formulations do not contain standard preservatives, they still can be harmful to ocular surface due to other excipients. In this study, we compared tolerability of commercial preservative-free (pf) prostaglandin analogues (pf tafluprost, pf latanoprost and pf bimatoprost) in long-term topical application in rabbits in vivo. We found that after eight weeks treatment, pf latanoprost was the worst tolerated among the tested drops. It expressed increased conjunctival redness and blinking frequency. Furthermore, it caused increased LDH release in the aqueous humour, infiltration of macrophages in the eyelids and visible defects in conjunctival goblet cells. However, we did not detect increased levels of inflammatory markers in the tear fluid or in the aqueous humour. Based on our study, we suspect that these negative effects are related to excipients included in pf latanoprost formulation.


Assuntos
Olho/efeitos dos fármacos , Olho/imunologia , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Prostaglandinas Sintéticas/administração & dosagem , Prostaglandinas Sintéticas/efeitos adversos , Administração Tópica , Animais , Biomarcadores/metabolismo , Piscadela/efeitos dos fármacos , Núcleo Celular/efeitos dos fármacos , Túnica Conjuntiva/efeitos dos fármacos , Proteínas de Ligação a DNA/metabolismo , Olho/metabolismo , Pálpebras/citologia , Pálpebras/efeitos dos fármacos , Feminino , L-Lactato Desidrogenase/metabolismo , Conservantes Farmacêuticos , Prostaglandinas Sintéticas/química , Coelhos , Fatores de Tempo
9.
Oncotarget ; 7(2): 1717-31, 2016 Jan 12.
Artigo em Inglês | MEDLINE | ID: mdl-26636537

RESUMO

Burkitt lymphoma is a fast-growing tumor derived from germinal center B cells. It is mainly treated with aggressive chemotherapy, therefore novel therapeutic approaches are needed due to treatment toxicity and developing resistance. Disturbance of red-ox homeostasis has recently emerged as an efficient antitumor strategy. Peroxiredoxins (PRDXs) are thioredoxin-family antioxidant enzymes that scavenge cellular peroxides and contribute to red-ox homeostasis. PRDXs are robustly expressed in various malignancies and critically involved in cell proliferation, differentiation and apoptosis. To elucidate potential role of PRDXs in lymphoma, we studied their expression level in B cell-derived primary lymphoma cells as well as in cell lines. We found that PRDX1 and PRDX2 are upregulated in tumor B cells as compared with normal counterparts. Concomitant knockdown of PRDX1 and PRDX2 significantly attenuated the growth rate of lymphoma cells. Furthermore, in human Burkitt lymphoma cell lines, we isolated dimeric 2-cysteine peroxiredoxins as targets for SK053, a novel thiol-specific small-molecule peptidomimetic with antitumor activity. We observed that treatment of lymphoma cells with SK053 triggers formation of covalent PRDX dimers, accumulation of intracellular reactive oxygen species, phosphorylation of ERK1/2 and AKT and leads to cell cycle arrest and apoptosis. Based on site-directed mutagenesis and modeling studies, we propose a mechanism of SK053-mediated PRDX crosslinking, involving double thioalkylation of active site cysteine residues. Altogether, our results suggest that peroxiredoxins are novel therapeutic targets in Burkitt lymphoma and provide the basis for new approaches to the treatment of this disease.


Assuntos
Linfócitos B/metabolismo , Proliferação de Células/efeitos dos fármacos , Peroxirredoxinas/metabolismo , Antineoplásicos/química , Antineoplásicos/metabolismo , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Linfócitos B/efeitos dos fármacos , Linfócitos B/patologia , Linfoma de Burkitt/metabolismo , Linfoma de Burkitt/patologia , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Células Cultivadas , Cisteína/química , Cisteína/metabolismo , Dipeptídeos/química , Dipeptídeos/metabolismo , Dipeptídeos/farmacologia , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Células HEK293 , Humanos , Metacrilatos/química , Metacrilatos/metabolismo , Metacrilatos/farmacologia , Modelos Moleculares , Estrutura Molecular , Peroxirredoxinas/antagonistas & inibidores , Peroxirredoxinas/química , Fosforilação/efeitos dos fármacos , Domínios Proteicos , Multimerização Proteica , Proteínas Proto-Oncogênicas c-akt/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Regulação para Cima
10.
Biochem Pharmacol ; 89(2): 210-6, 2014 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-24630929

RESUMO

Adenanthin has been recently shown to inhibit the enzymatic activities of peroxiredoxins (Prdx) I and II through its functional α,ß-unsaturated ketone group serving as a Michael acceptor. A similar group is found in SK053, a compound recently developed by our group to target the thioredoxin-thioredoxin reductase (Trx-TrxR) system. This work provides evidence that next to Prdx I and II adenanthin targets additional proteins including thioredoxin-thioredoxin reductase system as well as protein disulfide isomerase (PDI) that contain a characteristic structural motif, referred to as a thioredoxin fold. Adenanthin inhibits the activity of Trx-TR system and PDI in vitro in the insulin reduction assay and decreases the activity of Trx in cultured cells. Moreover, we identified Trx-1 as an adenanthin binding protein in cells incubated with biotinylated adenanthin as an affinity probe. The results of our studies indicate that adenanthin is a mechanism-selective, rather than an enzyme-specific inhibitor of enzymes containing readily accessible, nucleophilic cysteines. This observation might be of importance in considering potential therapeutic applications of adenanthin to include a range of diseases, where aberrant activity of Prdx, Trx-TrxR and PDI is involved in their pathogenesis.


Assuntos
Dissulfetos/metabolismo , Diterpenos/administração & dosagem , Isodon , Componentes Aéreos da Planta , Extratos Vegetais/metabolismo , Tiorredoxinas/antagonistas & inibidores , Tiorredoxinas/metabolismo , Linhagem Celular Tumoral , Dissulfetos/química , Diterpenos/química , Diterpenos/metabolismo , Células HEK293 , Humanos , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Transporte Proteico/efeitos dos fármacos , Transporte Proteico/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA